Monoclonal antibodies against SARS-CoV-2 were considered a promising approach for the prevention and therapy of coronavirus ...

A second-generation anti-CD40 therapy that inhibits B- and T-cell activity nearly eliminated multiple sclerosis activity over ...

New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, ...

Joe Walsh is the first Alzheimer's patient to be treated with an experimental nasal spray designed to reduce inflammation in ...

Sibeprenlimab targets a protein called A proliferation-inducing ligand (APRIL), and the drug is designed to limit the ...

AI can help identify women who might be helped by cancer therapies that target HER2, a protein that spurs on the growth of ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.